NCT00351039 - Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

Bevacizumab

Treatment Regimen Item 1: Bevacizumab 10 mg/Kg I. V. Day 1 and Day 15. Repeat cycles every 28 days.

DRUG

Erlotinib

Treatment Regimen Item 2: Erlotinib 150mg Per Orally (PO) Once Daily (QD) for 7 days starting day 2 and day 15. Repeat cycles every 28 days.

DRUG

Pemetrexed

Treatment Regimen Item 3: Premetrexed 500mg/m2 I.V. Day 1 and Day 15. Repeat cycles every 28 days.

Trial Locations (1)

H. Lee Moffitt Cancer Center & Research Institute, Tampa